The Motley Fool

Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim

Can Recursion accelerate the time frame for drug discovery? Last year, Recursion announced that tech giant Nvidia invested $50 million into its operations. Together, the businesses are working on drug ...
Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
CNBC

Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
Yahoo Finance

Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Motley Fool

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...